Tissue-specific overexpression of the human systemic amyloid precursor transthyretin (TTR) ameliorates Alzheimer's disease (AD) phenotypes in APP23 mice. TTR-␤-amyloid (A␤) complexes have been isolated from APP23 and some human AD brains. We now show that substoichiometric concentrations of TTR tetramers suppress A␤ aggregation in vitro via an interaction between the thyroxine binding pocket of the TTR tetramer and A␤ residues 18 -21 (nuclear magnetic resonance and epitope mapping). The K D is micromolar, and the stoichiometry is Ͻ1 for the interaction (isothermal titration calorimetry). Similar experiments show that engineered monomeric TTR, the best inhibitor of A␤ fibril formation in vitro, did not bind A␤ monomers in liquid phase, suggesting that inhibition of fibrillogenesis is mediated by TTR tetramer binding to A␤ monomer and both tetramer and monomer binding of A␤ oligomers. The thousandfold greater concentration of tetramer relative to monomer in vivo makes it the likely suppressor of A␤ aggregation and disease in the APP23 mice.
Introduction
The first suggestion of a salutary functional interaction between transthyretin (TTR) and ␤-amyloid (A␤) peptides in vivo came from experiments in which coexpression of wild-type (WT) human TTR (huTTR) and A␤ in Caenorhabditis elegans muscle cells resulted in normalization of the abnormal motility seen when the A␤ construct was expressed alone (Link, 1995) . A later study demonstrated that unilateral cerebral injection of anti-TTR antibody in Tg2576 A␤ transgenic mice enhanced A␤-associated pathology on the side of the injection relative to the non-injected hemisphere presumably by lowering the free TTR concentration on the injected side (Stein et al., 2004) . More recently, controlled studies from our laboratory showed that genetically programmed overexpression of a WT human TTR transgene suppressed both the neuropathologic and behavioral abnormalities seen in the well validated APP23 transgenic mouse model of human A␤ deposition and that silencing the endogenous Ttr gene accelerated the appearance of A␤-associated neuropathology, a finding made independently in APPswe/PS1⌬E9 transgenic mice (Choi et al., 2007; . Collectively, these experiments indicate that the early in vitro studies leading to the proposal that TTR "sequestered" A␤, protecting the brain from the effects of Alzheimer's disease (AD), might be correct in concept, if not in detail (Schwarzman et al., 1994) .
Experiments exploring the mechanism underlying the apparent beneficial effect of TTR on AD showed that most (70%) hippocampal and cortical neurons from human AD brains stain with an antibody for TTR as do all such neurons in APP23 and Tg2576 mice (Stein and Johnson, 2002; Li et al., 2011) . Endogenous Ttr transcription is increased in both adult APP23 brains and primary neurons cultured from 14-to 16-d-old APP23 embryos (Li et al., 2011) . TTR-A␤ complexes can be coimmunoprecipitated from APP23 cortical lysates and from similar preparations of some human AD brains (Li et al., 2011) . Studies in which A␤ or A␤ are preincubated with TTR have demonstrated TTR inhibition of A␤-induced cytotoxicity in a variety of assay systems (Mazur-Kolecka et al., 1995; Giunta et al., 2005; Costa et al., 2008b; Li et al., 2011) .
In vitro surface plasmon resonance (SPR) experiments showed that both TTR monomer and tetramer bound to immobilized A␤ monomers and fibrils, whereas ELISA filter-bindingbased assays indicated that TTR monomer is the major binder of A␤ monomer in vitro Du and Murphy, 2010) . In an effort to further understand the biochemical mech-anism underlying the ameliorative effect of TTR on A␤ aggregation-associated toxicity in vivo, we used TTRs with varying thermodynamic and kinetic stabilities to examine the relationship between TTR tetramer stability, binding to A␤, and inhibition of A␤ aggregation in vitro with liquid-phase binding assays, including isothermal titration calorimetry (ITC) and nuclear magnetic resonance (NMR) spectroscopy, SPR, and solidphase assays of binding of TTR or A␤ conformers bound to nitrocellulose or plastic.
Materials and Methods
Recombinant TTR and synthetic A␤ preparation. Recombinant TTR [WT huTTR, T119M, K15A, V30M, V122I, mouse TTR (muTTR), and human monomeric TTR (M-TTR; WT TTR with the substitutions F87M/ L110M that does not tetramerize)], 15 N, 2 H-labeled huTTR, 15 N, 2 Hlabeled TTRV30M, and 15 N-labeled M-TTR were prepared in an Escherichia coli system and purified using fast protein liquid chromatography and gel filtration as described previously (Reixach et al., 2008) . A␤ and A␤ 1-42 were synthesized and purified by HPLC, and their identity was confirmed by mass spectrometry as described previously (Du et al., 2011) .
A␤ monomerization. Lyophilized A␤ powder was monomerized as described previously (Du et al., 2011; Li et al., 2011) if not indicated. Briefly, A␤ was dissolved in 2 mM NaOH at 2.5 mg/ml and pH was adjusted to 10.5 before being sonicated in cold water bath for 30 min. The solution was filtered through 10 kDa cutoff centricon filter (Millipore), and its concentration was determined by UV absorbance at 280 nm ( ϭ 1280 M Ϫ1 cm Ϫ1 ). A␤ aggregation assay. Initially monomeric synthetic A␤ 1-40 (10 M) and 20 M thioflavin T (ThT) in NaPi (50 mM sodium phosphate, 150 mM NaCl at pH 7.4) were mixed, and 100 l of the mixture was added to a 96-well plate (Costar) and sealed with a microplate cover. Fluorescence intensity was recorded every 10 min at 37°C after agitation of 5 s with excitation/emission wavelengths of 420/485 nm (Tecan Safire II; Tecan). The half-maximal fluorescence time point (t 50 ), calculated as the time ThT fluorescence reached the midpoint between lag phase and postaggregation plateau, was used to describe the aggregation properties of A␤. At least three replicates were measured for each treatment (Cohen et al., 2006) .
To test the effect of TTR variants on A␤ aggregation, buffer or TTR variants (muTTR, K15A, T119M, huTTR, V30M, V122I, were added to the A␤ 1-40 aggregation assays to a final concentration of 0.25, 0.5, 1, and 2 M. The experiment was repeated, and a representative experiment was graphed. Incubations of TTR alone under these conditions did not result in an increase in ThT fluorescence and were not graphed.
A␤-derived diffusible ligands. Lyophilized A␤ 1-42 was dissolved in hexafluoro-2-propanol (HFIP; Sigma-Aldrich), evaporated under nitrogen stream at room temperature. During usage, A␤ was resuspended in anhydrous DMSO (Sigma-Aldrich) to 5 mM, vortexed for 10 s, and then sonicated for 10 min. A␤ was then diluted with ice-cold phenol red-free Ham's F-12 (Caissonlabs) to a final concentration of 60 M either with or without 6 M TTR (huTTR, muTTR, and M-TTR) and incubated at 4°C for 2 d (Lambert et al., 1998) .
Western blots. Samples were mixed with Tris-tricine sample buffer and separated on 15% Tris-tricine SDS-PAGE. The proteins were transferred onto a PVDF (Bio-Rad) membrane, and the blots were blocked with 5% dry milk, incubated in primary antibody (Covance 6E10 anti-A␤ or Dako anti-TTR) for 1 h and then secondary antibody (IRDye secondary antibody), imaged, and quantified using an Odyssey system (LI-COR Biosciences).
Light scattering. huTTR (10 M in NaPi) was mixed with A␤ 1-40 monomer (10 M) in a 20 ml disposable scintillation vial at room temperature quiescently for 1 d and then loaded into a Dawn EOS lightscattering photometer (Wyatt Technology). Light-scattering intensity data at 90 o were recorded every 2 s over the course of 120 min at 37°C. 8-Anilino-1-naphthalene sulfonate monitored A␤ 1-42 aggregation. A␤ 1-42 (25 M) aggregation alone or in the presence of 2.5 M huTTR, muTTR, or M-TTR at pH 7.4 with agitation was monitored by 8-anilino-1-naphthalene sulfonate (ANS; Sigma-Aldrich) binding (which increased fluorescence intensity with A␤ aggregation). When ANS fluorescence was monitored ( excitation of 380 nm), the emission wavelength increased from day 0 through day 2, corresponding to the formation of oligomers on days 1 and 2.
Transmission electron microscopy. Transmission electron microscopy (TEM) analysis of the inhibition of A␤ aggregation by huTTR, muTTR, and M-TTR was performed by incubation of 25 M A␤ 1-40 alone or with 25 M TTRs (100 M M-TTR to achieve the same A␤/TTR monomer ratios) in NaPi at 37°C in a 96-well plate for 5 d. The TEM grids were prepared by adding 5 l of preformed fibrils onto copper grids, covered with Formvar and carbon films, and counterstained with 2% (w/v) uranyl acetate, using the droplet technique. Specimens were examined with a Zeiss 900 electron microscope operated at an acceleration voltage of 80 kV. Magnification of 30,000ϫ was used for imaging.
Atomic force microscopy imaging TTR inhibition of A␤ aggregation. huTTR, muTTR, or M-TTR at 2.5 M was added to 25 M A␤ 1-42 aggregation in 0.1ϫ PBS buffer. The mixture was shaken at 300 rpm at 25°C. Samples were spotted on mica and absorbed for 30 min before being washed and dried. Images were taken using an Asylum Research MFP 3D atomic force microscopy (AFM) system as described previously (Ladiwala et al., 2012) . Representative images (3 ϫ 3 m) were presented for samples taken at days 0, 1, 2, and 5.
SPR. Sensor chip CM5 (GE Healthcare) was preconditioned by running 20 l of 0.1% HCl, 50 mM NaOH, 0.1% SDS, and 0.085% H 3 PO 4 at a speed of 20 l/min using the BIACORE3000 (GE Healthcare). Monomeric A␤ 1-40 peptide was immobilized using an amine coupling kit (GE Healthcare) per the recommendation of the manufacturer. NaOH at 2 mM and 150 mM NaCl were used as a regenerant. To compare the relative binding among TTRs to A␤, 20 M TTR was allowed to flow through the cell for 3 min at 40 l/min. Each experiment was performed on a new chip double referenced with buffer before and after sample injection, and response units (RUs) were normalized to the initial plateau. Two thousand two hundred to 2600 RUs of A␤ monomer was immobilized.
ITC. Direct interactions between TTRs and A␤ 1-40 were studied on a Microcal iTC 200 system (GE healthcare). TTRs were dialyzed overnight at 4°C against 25 mM HEPES buffer, pH 7.0, obtained by diluting 1 M HEPES buffer, pH 8.0 (Mediatech), with MilliQ water. Lyophilized A␤ 1-40 powder was dissolved in HFIP for 1 h and evaporated in a fume hood (Wang et al., 2010) . HEPES buffer at 25 mM (Brockhaus et al., 2007) was then added to the tubes, vortexed, and centrifuged at 13,000 ϫ g for 10 min at 4°C to pellet insoluble A␤. For the titration experiment, TTRs were present in the cell and A␤ in the syringe. Injections were performed at 37°C. Control titrations included A␤ 1-40 to buffer and buffer to TTRs (data not shown). Control titrations of A␤ 1-40 into buffer were subtracted from all the experiments. In each experiment, 16 injections of 2.5 l A␤ with 180 s intervals were made with syringe stirring speed of 1000 rpm. The experimental titrations were performed using at least three different concentrations of both TTRs (19, 25, 30, 35 M) and A␤ (190, 250, 300, 350 M) while maintaining a 10:1 ratio. All gave similar results. Stoichiometry (N), binding constant (K D ), enthalpy (⌬H ) and entropy (⌬S) were calculated from the fitting curves using Origin 7.0 from Microcal.
NMR spectroscopy. NMR spectra were recorded using Bruker DRX 600 and Avance 800 MHz spectrometers. Assignments for TTR, V30M, and M-TTR were made using standard multidimensional triple-resonance NMR experiments (Cavanagh et al., 2007 and A␤ 1-42 were first monomerized as described above (see A␤ monomerization). Monomeric A␤ 1-40 or A␤ 1-42 at 80 M with or without 20 M M-TTR, huTTR, or TTRK15A was incubated with agitation at 280 rpm in NaPi for 3 d at 37°C. The mixtures were analyzed on 15% native Tris-tricine SDS PAGE gels, transferred to PVDF membranes, and probed with anti-A␤ (6E10) and anti-TTR (Dako) antibodies. Images were obtained using the Odyssey system (LI-COR; Fig. 6 , A␤, green; TTR, red; left panels, A␤ alone; right panels, merge of A␤ and TTR). Under these conditions, A␤ (alone) aggregation results in a heterogeneous smear and large aggregates trapped at the top of the gels. No smear or trapped material is seen in the presence of M-TTR (Fig. 6 , red arrows). The major A␤ species in the M-TTR lanes had mobilities consistent with an A␤ pentamer and decamer (Fig. 6 , yellow arrows). The distribution of A␤ aggregates in the lanes showing interaction with huTTR tetramer was intermediate between M-TTR and TTRK15A.
Dot-blot epitope mapping TTR-A␤ 1-42 binding site. A␤ 1-42 (American Peptide) was dissolved in an aqueous 50% acetonitrile solution (1 mg/ml). The peptide was aliquoted, lyophilized, and then stored at Ϫ20°C. A␤ oligomers were prepared by dissolving the peptide in 100% HFIP (Fluka). The solvent was evaporated, and A␤ was dissolved in 50 mM NaOH (1 mg/ml A␤), sonicated (30 s), and diluted in PBS (25 M A␤). The A␤ peptide was then centrifuged (22,000 ϫ g for 30 min), and the pelleted fraction (5% of starting volume) was discarded. The supernatant was incubated at 25°C for 1-3 d without agitation to form prefibrillar oligomers (A11-positive) or 4 -6 d to form A11-negative oligomers. Fibrils were formed in the same way except that monomers were mixed with preexisting fibrils (10 -20 weight percent seed) without agitation for 24 h at 25°C. To identify the TTR binding site on A␤, 220 ng of A␤ 1-42 conformers were spotted on nitrocellulose membranes (Hybond ECL; GE Healthcare) and then incubated with sequence specific antibodies for epitopes present on A␤, including the following: N-terminal A␤ 3-10 , 6E10 (Sigma-Aldrich); middle A␤ 18 -22 , 4G8 (Covance); A␤ 16 -21 , A3356; C-terminal, A␤ 30 -35 (Sigma-Aldrich); and A␤ 35-39 , 9F1 (Santa Cruz Biotechnology) at 25°C for 2 h in blocking buffer. The blot was washed with PBST (PBS with 0.05% Tween 20) and incubated with 10 M biotinylated TTR at 4°C overnight. The blot was washed again and incubated with streptavidin-conjugated HRP and developed.
Quantification of binding strength of TTR and A␤ conformers. The TTR was biotinylated with Sulfo-NHS-Biotin (Pierce). Approximately 2 g of A␤ fibrils, oligomers (A11 positive), or monomers (prepared as in the previous section) were immobilized in 96-well plates (Nunc Maxisorb; Thermo Fisher Scientific), and biotinylated TTR was added at various concentrations. The plate were washed (three times, PBST) and developed using avidin-HRP. The IC 50 values were calculated using SigmaPlot.
Brain lysate ELISA. Brain tissue (cortices, 60 mg) of APP23 mice of either sex overexpressing huTTR without endogenous muTTR (APP23/TTR ϩ /Ttr Ϫ ) was homogenized in 800 l of Tris buffer [50 mM Tris, 150 mM NaCl, and 3 mM EDTA with protease inhibitors (Roche), pH 7.5] on ice. The lysate was centrifuged at 21,000 ϫ g at 4°C for 4 min, and the supernatant was collected as representing the extracellular fraction. The pellet was rehomogenized in Triton buffer (Tris buffer with 0.5% Triton X-100) and centrifuged at 21,000 ϫ g, and the supernatant was collected as Triton extracts (intracellular fraction). The pellet was dissolved in 2% SDS and spun again at room temperature, and the samples were stored at Ϫ80°C. ELISA plates (Immulon 4 HBX; Thermo Fisher Scientific) were coated with primary antibody (Dako or 6E10) in 50 mM carbonate buffer, pH 9.6, at 4°C overnight. The plate was washed with TBST (Tris buffered saline with 0.05% Tween 20) and blocked with 5% non-fat milk in TBST. The samples and standard (recombinant huTTR or synthetic A␤ 1-40 ) in blocking buffer were incubated on the plate for 2 h at 37°C. The alkaline phospha- . E, Light scattering shows that huTTR and A␤ 1-40 coincubation resulted in smaller aggregates compared with A␤ 1-40 incubated alone, demonstrating that huTTR inhibited A␤ oligomer formation. F, M-TTR or huTTR were added to A␤ (1:10 molar ratio) during ADDLs preparation. The products were analyzed by Western blot probed with 6E10 against A␤. M-TTR and huTTR both inhibited large oligomer formation by A␤ 1-42 .
tase (Dojindo)-labeled goat anti-human preablumin (Meridian Life Science) or biotin-4G8 (Covance) was incubated for 1 h at 37°C. For TTR detection, 0.5 mg/ml p-nitrophenylphosphate (NPP; Sigma-Aldrich) in NPP buffer (10 mM diethanolamine, 0.5 mM MgCl 2 ) was added, and the plate was read by SpectroMAX (Molecular Devices) at 405 nm. For A␤ detection, the plate was incubated with 0.04% streptavidin-HRP (Invitrogen) for 1 h at room temperature before being developed using QnataBlue kit (Thermo Fisher Scientific) and read at excitation/emission at 340/400 nm (Tecan Safire II; Tecan).
TTRs did not disrupt preformed A␤ aggregates. The disaggregation assay was designed to investigate whether TTR disaggregates or digests mature A␤ fibrils. Monomeric A␤ 1-40 (10 M) was aggregated into fibrils in a black 96-well plate in NaPi buffer for 5 d. ThT at 20 M and 1 M TTRs (huTTR, muTTR, and M-TTR) were added to 100 l of fibril mixture, and fluorescent intensity was recorded for 5 d. The ThT fluorescence intensity was normalized against that of the day 0 when TTR was added to the fibrils.
TTRs (10 M) incubated quiescently with preformed A␤ 1-42 oligomers and fibrils (25 M) for 24 h, and AFM analysis of the incubation showed that the quantity and conformation of A␤ aggregates did not change in the presence of TTR over this period.
Statistical analyses. Statistical analysis was performed in Minitab 13 (Minitab). Post hoc analysis was performed when the ANOVA result was significant. For aggregation assays, post hoc Dunnett's simultaneous tests were performed. The t 50 values were compared only with the samples on the same plate, and representative data were plotted. For quantification of inhibition of oligomer formation on Western blot, the Bonferroni's correction was used for t tests. For aggregation assays, one-way ANOVA was used, followed by post hoc t tests with Bonferroni's corrections. Means Ϯ SD were graphed for all experiments. For each treatment, the replicates were more than three, and each experiment was repeated at least twice. Significance is shown at *p Ͻ 0.05 and **p Ͻ 0.01. (WT), muTTR, which is 80% homologous to huTTR but kinetically much more stable (Reixach et al., 2008) , and M-TTR, an engineered human TTR monomer that contains mutations (F87M/L110M) that alter the monomer-monomer interface preventing tetramer formation under physiologic conditions ). We measured the t 50 values of A␤ aggregation (time required to reach half-maximal ThT fluorescence) in the presence of each of the TTRs (Fig. 1A) . The rank order of inhibitory capacity is M-TTR Ͼ huTTR Ͼ muTTR, and it is concentration dependent for all forms of TTR. TEM confirmed that no fibrils were formed when A␤ 1-40 was coincubated with any of the TTRs at high concentrations (25 M TTR/25 M A␤ 1-40 ; Fig. 1B) .
Results

TTRs inhibit A␤ fibril and oligomer formation
AFM studies of mixtures of TTR (2.5 M) and A␤ 1-42 (25 M) incubated for 5 d with agitation show that M-TTR completely inhibited A␤ aggregation. huTTR reduced the quantity of A␤ fibrils formed, and muTTR had no detectable effect (Fig. 1C) . The findings were similar when A␤ 1-42 aggregation was monitored by ANS, which shifts its maximum fluorescence emission spectrum on A␤ aggregation. The shift was inhibited by M-TTR but not huTTR or muTTR (Fig. 1D ). These analyses suggest that the inhibitory capacities of various TTRs varied depending on the assay (as well as whether aggregation of A␤ 1-40 or A␤ 1-42 is being analyzed); however, in most assays, the order of inhibitory capacity was M-TTR Ͼ huTTR Ͼ muTTR.
It is thought that A␤ oligomers (rather than fibrils) are the toxic species in AD. They have been shown to increase Ca 2ϩ influx, induce the generation of reactive oxygen species, and decrease the viability of primary cultured neurons and a variety of cultured cell lines (Walsh et al., 2002; De Felice et al., 2007; Wang et al., 2009; Li et al., 2011) . To study the effect of TTR on A␤ oligomer formation, A␤ 1-40 monomer was incubated in the presence or absence of huTTR at room temperature without agitation, conditions known to result in oligomer but not fibril formation (Sarroukh et al., 2011) . Light-scattering analysis showed that the oligomeric A␤ aggregates formed in the presence of huTTR were smaller than those formed in the absence of TTR (Fig. 1E ). When tetrameric huTTR or M-TTR was added during the preparation of toxic A␤ 1-42 oligomers [A␤-derived diffusible ligands (ADDLs)], the proportion of large A␤ oligomers (37-75 kDa) present was greatly reduced (t test, n ϭ 4, Bonferroni's correction, p Ͻ 0.05), with M-TTR being more effective than huTTR in reducing large oligomer formation (Fig. 1F ) . In addition, the fraction of A␤ remaining as monomer was greater in the presence of both M-TTR and huTTR. The results suggest that TTR inhibits A␤ fibril formation by reducing oligomer formation and/or suppressing the conversion of A␤ oligomers to larger oligomers, which can serve as fibril seeds that can initiate/ accelerate A␤ fibrillogenesis in vitro.
To examine the mechanism of inhibition in greater detail, we compared the abilities of recombinant TTRs of different kinetic and thermodynamic stabilities to inhibit A␤ 1-40 fibril formation. We reasoned that, because monomeric TTR was the best inhibitor of in vitro fibrillogenesis and is generated by tetramer dissociation, perhaps inhibition of fibril formation required a dissociation step. We used WT huTTR tetramer, several destabilized naturally occurring huTTR mutant tetramers, naturally occurring and engineered kinetically stable tetramers and M-TTR ( Fig. 2A) . By adding identical molar concentrations of the different TTRs to the aggregation reaction (containing the same amount of A␤ 1-40 ) at time 0 and calculating the t 50 value, we could compare the relative abilities of various TTRs to inhibit fibril formation. At 0.25 M, the approximate TTR concentration in human CSF, huTTR, TTRV122I, and M-TTR significantly suppressed aggregation of a 10 M A␤ solution (an A␤ concentration far in excess of that found in vivo; Dunnett's test, p Ͻ 0.05; Figs. 1A, 2B ). At 0.5 M, TTRT119M and TTRV30M (TTR tetramers with increased kinetic stability) also inhibited A␤ 1-40 fibril formation (Dunnett's test, p Ͻ 0.05). At higher concentrations (up to 2 M, a 1:5 molar ratio of TTR/A␤), all TTRs tested, regardless of their thermodynamic or kinetic stability, significantly delayed A␤ fibril formation. The results demonstrated a concentration-dependent effect on the inhibition of A␤ 1-40 fibril formation. It is interesting to note that, under these conditions, the most kinetically unstable tetramer, i.e., TTRV122I, was a better inhibitor of aggregation than the thermodynamically unstable TTRV30M mutant. However, even the rare highly kinetically stable variant TTRT119M could suppress A␤ aggregation at TTR concentrations within the range found in human serum (3-5 M), indicating that in vitro, although M-TTR was the best inhibitor of aggregation, TTR tetramer dissociation to monomer was not required for suppression.
We assumed that the extent of inhibition of A␤ fibril formation would be related to the affinities of the various TTRs for the A␤ monomer because the monomer is required for the oligomerization that forms the nucleus apparently required for fibrillogenesis. This appeared to be true when the relative association between the various TTRs and A␤ 1-40 monomer were measured by SPR (Fig. 3A) , with A␤ immobilized to a dextran matrix and the interaction measured in a relatively rapid timeframe. The rank order of association was M-TTR Ͼ TTRV30M Ն huTTR Ͼ TTRV122I ϭ TTRT119M Ͼ TTRK15A. When TTR binding was compared in terms of the molar concentration of monomer, M-TTR bound A␤ 1-40 monomer best. Of the TTR tetramers tested, TTRV30M and WT were the strongest binders to A␤ 1-40 , and TTRK15A (a highly kinetically stable engineered huTTR variant) was the weakest. Thus, the relative association of various TTRs with A␤ monomers, as measured by SPR, may be related to their stabilities when the correlation is based on experimentally determined "combined stability scores" (Sekijima et al., 2005) . However, the relationship is not statistically significant ( p Ͼ 0.05).
It is known that TTR, as a systemic amyloidogenic precursor, aggregates in vitro. However, consistent with published data (Hammarström et al., 2002) , TTR incubated alone under the conditions of our experiments (NaPi buffer at neutral pH) did not aggregate as monitored by either ThT fluorescence or AFM/ TEM microscopy (data not shown).
To determine the concentrations of TTR and A␤ present in vivo in circumstances in which TTR had been shown to inhibit the behavioral and neuropathologic manifestations of A␤ deposition, we performed TTR and A␤ specific ELISAs on Tris extracts of the cerebral cortices of APP23 mice overexpressing WT huTTR. The TTR concentration was 1.4 Ϯ 0.4 M, whereas the soluble A␤ concentration was 0.7 Ϯ 0.5 nM (n ϭ 12).
ITC of TTR-A␤ interaction
ITC analysis of huTTR, muTTR, and M-TTR binding to A␤ 1-40 monomer showed that, despite their great differences in inhibit- ing A␤ fibril formation, human and mouse tetrameric TTRs bound A␤ 1-40 with similar affinities, with K D values in the micromolar range (Fig. 3 B, C) . The huTTR-A␤ and muTTR-A␤ interactions were enthalpy driven (⌬H Ͻ 0), with muTTR appearing to have a higher change in enthalpy than huTTR (Fig. 3 B, C,E) . It is unclear whether the entropy factor is favorable or unfavorable for the huTTR-A␤ interaction, whereas it appeared to be strongly unfavorable (ϪT⌬S Ͼ 0) in the muTTR-A␤ interaction. Surprisingly, despite M-TTR being the most effective inhibitor of A␤ aggregation, the M-TTR-A␤ interaction did not exhibit an exothermic isotherm under the same ITC conditions used for TTR tetramers (Fig.  3D ), indicating that, under these conditions, it did not bind monomeric A␤ or that the interaction did not result in a detectable heat change.
TTRs bind A␤ in the thyroxine site of TTR
To further elucidate the structural basis of huTTR binding to A␤ monomer, we acquired two-dimensional 1 H-15 N HSQC NMR spectra to identify the A␤ monomer binding sites on tetrameric WT huTTR and TTRV30M. We recorded the TROSY-HSQC spectra of huTTR or TTRV30M tetramers (each at 25 M) in the absence and presence of A␤ 1-40 (80 M; Fig.  4 A, B) . The majority of HSQC crosspeaks remain unchanged or only marginally shifted on A␤ addition, suggesting that the native TTR tetramer structure was not affected by binding A␤ monomer. However, significant changes were observed for several cross-peaks corresponding to amino acids that could be involved in the TTR-A␤ interaction.
Residues in or around the thyroxine (T 4 ) binding site (i.e., L17, T106, A108, L110, and V121; Hamilton and Benson, 2001 ) exhibited the greatest changes in chemical shift during binding to A␤, i.e., Lys15, Leu17, Ile107, Ala108, Ala109, Leu110, Ala120, Val121, and Val122 (Fig.  4C,D, blue patches) . Similar shifts in residues close to the T 4 binding site (Met13, Val16, Ala109, Leu110, Ala120, Val121, and Val122) were also observed in WT huTTR (Fig. 4B) . The findings suggest a crucial role of this region in the binding of A␤ monomer by TTR. In addition, residues in the A-B loop/helix, which were adjacent to the T 4 binding site, i.e., Ala19, Val20, Gly22, Ser23, Ala25, and Asp27 (Fig. 4C,D, red) , exhibited shifted resonances. Although these residues showed significant chemical shift changes, they might not reflect direct interaction with A␤ but rather report on conformational perturbations induced by the interaction between A␤ and the T 4 binding pocket. Similarly, the chemical shift change of Trp79 was likely to be related to the fact that its side chain pointed toward the T 4 binding site and the A-B loop (Fig. 4D) . The relevance of the (Fig. 5A) . No chemical shift changes were observed in the regions known to be involved in TTRretinol binding protein interaction (Monaco et al., 1995) .
Intriguingly, despite its potent inhibition of A␤ fibril formation, we observed no shifted cross-peaks in M-TTR after incubation with A␤ monomer (Fig. 5B) . The absence of such changes is consistent with the lack of a detectable signal in the ITC experiments in which M-TTR was titrated with A␤ monomer. Thus, our results demonstrate that M-TTR is a highly efficient inhibitor of A␤ fibrillogenesis in vitro, although it does not appear to bind A␤ monomer as measured by ITC or examined in the NMR experiments (Figs. 1A, 3D , 5B). These results suggest that the inhibitory activity of the monomer resides in its capacity to bind relatively small A␤ oligomers, formed over a longer time than measured by ITC, which prevents additional assembly beyond tetra/pentamers or nono/decamers (Fig. 6 A, B , lanes of A␤ϩM-TTR).
TTR binding to A␤ involves A␤ amino acids 18 -21
To determine the TTR binding site on A␤, A␤ 1-42 monomer and aggregates were immobilized on nitrocellulose and probed with antibodies specific for epitopes formed by different regions of the peptide (Kayed et al., 2003; Ladiwala et al., 2011) . The antibodies interacting with the central hydrophobic region of A␤, i.e., residues 18VFFAE22 (4G8) and residues 16KLVFFA21 (A3356), abolished the TTR/A␤ 1-42 interaction as monitored by the biotin-TTR-streptavidin-HRP (conjugated horseradish peroxidase) system (Fig. 7A) . The results are consistent for both tetrameric and monomeric TTR and for all A␤ conformers that were assayed.
The binding capacities (IC 50 values) of TTR (huTTR, muTTR, and M-TTR) to A␤ conformers to immobilized TTR (huTTR, muTTR, and M-TTR) on 96-well plates, measured as IC 50 , were also compared. In this assay, all TTRs bound to A␤ oligomers better than to A␤ fibrils (Fig. 7B) . M-TTR bound to all forms of A␤ aggregates and showed the strongest binding (the smallest IC 50 ) among three TTRs. M-TTR bound to all forms of A␤ aggregates better than huTTR. Both tetrameric TTRs bound to A␤ oligomers significantly better than to A␤ fibrils. In this assay, neither tetramer bound to A␤ monomers, whereas the strength of M-TTR binding to A␤ monomers was weak relative to its binding to A␤ aggregates under these conditions.
Discussion
Many observations have suggested an interaction between the systemic amyloid precursor TTR and the AD amyloid peptide A␤ (Riisøen, 1988; Hatterer et al., 1993; Schwarzman et al., 1994; Serot et al., 1997; Castano et al., 2006; Brettschneider et al., 2010; Schultz et al., 2010) . However, the specificity of the interaction was questioned in the absence of detailed characterization of the binding (for review, see Li and Buxbaum, 2011) . We used ITC to determine the K D and stoichiometry of the A␤ monomer-TTR tetramer interaction and NMR to characterize the A␤ binding site on TTR in vitro in solution. Our estimation of the K D differs substantially from previously estimated binding parameters of K S at 2300 M Ϫ1 (Liu and Murphy, 2006) by tryptophan fluorescence quenching and K D of 28 nM using competition binding (Costa et al., 2008b) . Our NMR data showed that the A␤ binding site on TTR involves amino acids in and around the T 4 binding site of the tetramer, partially confirming and extending the recently reported involvement of TTR residues L17, L110, and L82 (but S85) (Du et al., 2012; Yang et al., 2013) .
huTTR tetramers of varying stabilities and M-TTR inhibit A␤ oligomerization and fibril formation at substoichiometric concentrations, which is consistent with previous reports that TTRs inhibit A␤ fibril formation (Schwarzman et al., 2004; Liu and Murphy, 2006; Costa et al., 2008b) . However, when liquid-phase binding interactions are measured by ITC, M-TTR, the best inhibitor of A␤ aggregation, yields no heat signature and presumably does not bind monomeric A␤ under these conditions, whereas human and murine tetramers, which differ considerably in their inhibitory capacities, have similar binding characteristics.
The ITC data are reinforced by the NMR results in which binding of A␤ produces clear shifts in resonances of amino acids comprising the T 4 binding site of the human TTR tetramer. Experiments showing reduced inhibition of A␤ aggregation when the T 4 site is occupied by small molecules confirm its involvement in A␤ binding. These results are consistent with, but more definitive than, previous data from cross-linking experiments, alanine scanning mutagenesis, and peptide inhibition of TTR-A␤ interaction, which suggested major roles for residues L110 in strand G and L82 in the EF helix/loop in binding A␤ (Du et al., 2012; Yang et al., 2013) . Our data suggest that L82, rather than serving as an A␤ oligomer sensor (Yang et al., 2013) , may influence the orientation of the side chain of W79, which usually points to the T 4 binding site.
The relatively unstable TTRV30M tetramer shows resonance shifts of the same residues greater than those seen with WT hu- man TTR, indicating greater access of A␤ to the hydrophobic T 4 binding site of the tetramer, perhaps accounting for its greater capacity to inhibit fibrillogenesis. There were no shifts when M-TTR was incubated with monomeric A␤, despite its substantial capacity to inhibit A␤ aggregation but consistent with its lack of binding in the ITC experiments. The fact that M-TTR does not show interaction with A␤ monomer detectable by ITC or NMR, yet efficiently inhibits A␤ oligomer and fibril formation, strongly suggests that M-TTR binds species of A␤ other than monomer, most likely some form of A␤ oligomer. The data in Figure 6 are consistent with that hypothesis.
The data from solid-phase binding assays are not completely consistent with the characteristics of binding or inhibition of fibril formation in liquid phase, i.e., huTTR and muTTR, did not bind to A␤ monomer in dot blots or on the plate, whereas M-TTR bound very well, suggesting that the molecular surfaces available in liquid phase for interaction may not be equally accessible when various forms of A␤ are coupled to solid matrices or tethered to the dextran matrix of the Biacore chip. When A␤ was immobilized, we observed preferential binding of M-TTR to A␤ monomer, which is consistent with a previous report, although we found that this varies with the methods used (Du and Murphy, 2010) . Interestingly, in dot-blot assays, regardless of the form of TTR used or the aggregation state of A␤, specific binding for A␤ epitopes (18VFFA21) encompassing amino acids 16 -21, the region required for the formation of onpathway fibrillar aggregates (Ahmed et al., 2010) , is blocked, suggesting that the site is available to interact, presumably with either the hydrophobic T 4 binding site or the hydrophobic surface of M-TTR (Fig. 8) , confirming the previously reported involvement of residues 17-24 (Du and Murphy, 2010) .
In vitro, A␤ monomers adopt many conformations (Tomaselli et al., 2006) , creating an ensemble of aggregation intermediates among which are ␤-sheet-rich oligomers that seed on-pathway aggregation. The formation of such nuclei is the rate-limiting step in primary fibril formation (for review, see Dasilva et al., 2010) . In our experiments, the interaction between TTR tetramer (which does not form fibrils under the conditions of the experiments) and A␤ monomers reduced A␤ aggregation, presumably by removing A␤ from the pool of monomers with the exposed central hydrophobic region critical for ␤-sheet-rich oligomer formation, i.e., TTR tetramers inhibited A␤ seed formation at substoichiometric concentrations. In contrast, the hydrophobic surface of M-TTR (which does not tetramerize or aggregate under the same experimental conditions) can interact with A␤ oligomers to slow large oligomer formation. Given that TTR equilibrium greatly favors tetramer and evidence suggesting that A␤ does not destabilize the TTR tetramer (data not shown), tetrameric TTR is pre- Figure 8 . Mechanisms of TTR inhibition of A␤ aggregation in vitro. The majority of A␤ monomers aggregate into oligomers and fibrils and ultimately reach equilibrium in vitro. TTR tetramers bind the central hydrophobic region of A␤ monomer (at residues 18VFFA21) in the T 4 binding pocket and sequester the monomer from the oligomer forming pool and abolish A␤ form ␤-sheet structure. A small fraction (Hurshman Babbes et al., 2008) of WT TTR tetramers dissociate into monomers, which have the capacity to efficiently bind small A␤ oligomers, removing them from the fibril forming pathway and inhibiting additional A␤ aggregation. The excess of TTR tetramer relative to monomer in vivo suggests that the salutary effect of TTR on A␤ deposition is likely to take place via TTR tetramer and A␤ monomer association (dotted line circled area). Other alternatives include TTR tetramer interaction with A␤ oligomers and large fibrils, the destabilization of TTR tetramer by the binding of A␤ monomer in the T 4 pocket to yield free A␤-binding monomers (broken arrows), an effect that would be opposite to that of T 4 binding (which stabilizes the tetramer), or interaction of A␤ oligomers with TTR monomer in a cellular compartment before the formation of mature TTR tetramers. The precise anatomic site of interaction in vivo is unknown. sumably the major player in inhibition of A␤ aggregation in vivo (Fig. 8) .
Recently, it was proposed that interaction of A␤ monomer or small oligomers with TTR tetramer leads to tetramer dissociation and subsequent binding of oligomers by the dissociated monomers (Yang et al., 2013) . Our experiments indicate that tetramer dissociation is not required for inhibition of A␤ fibrillogenesis by various TTRs. We were also unable to demonstrate destabilization of TTR tetramers by incubation with A␤ 1-40 (data not shown).
What are the implications of these data for the apparent protective activity of TTR in transgenic murine models of A␤ deposition or in the context of human AD? The concentration of the A␤ monomer in human brains (and those of APP23 mice) in vivo is in the high picomolar to low nanomolar range (Cirrito et al., 2003; Moore et al., 2012) . The concentration of TTR tetramers in vivo is much higher (0.25-0.5 M in human CSF, 3-5 M in human serum). The predicted concentration of monomeric TTR, based on the WT TTR K association of 1.1 ϫ 10 24 M Ϫ3 (Hurshman Babbes et al., 2008) , is much lower (ϳ25 nM in CSF, ϳ46 nM in serum) and consistent with the observed human serum TTR monomer concentration (5-10 nM; Sekijima et al., 2001) . In soluble extracts of brains of APP23 mice in which the neuropathologic and behavioral abnormalities are suppressed by overexpressing huTTR, the concentration of huTTR is 2000 times than that of A␤ (1.4 M vs 0.7 nM). Thus, in vivo, whereas TTR monomer may be present in excess relative to A␤, the absolute amount of tetrameric TTR is 1000-fold greater. Assuming that there is no anatomic or cellular compartment in which TTR monomers are preferentially increased in the presence of A␤ oligomers, it appears that TTR tetramer binding to A␤ monomers and perhaps A␤ oligomers is the major mechanism of inhibition of A␤ fibrillogenesis in the brains of APP23 mice overexpressing huTTR (Fig. 8) .
Studies in hemizygous Igf1r knock-out mice carrying a human AD gene indicated that the mice formed large non-toxic oligomers (Cohen et al., 2009 ). The present experiments did not show that TTR drives A␤ aggregation to create large non-toxic, nonfibrillar aggregates when various forms of TTR were added to A␤ monomers at the start of the reaction. However, recent studies examining the interaction of TTR conformers with preformed toxic A␤ oligomers suggest that this may be the case (Cascella et al., 2013) . In contrast to another report (Costa et al., 2008a ), we could not detect disruption of preformed A␤ oligomers and fibrils by any of the TTRs tested (Fig. 9) .
TTR is present in the interstitial fluid of the brain because the choroid plexus secretes substantial amounts of the protein into the CSF. We also showed increased TTR synthesis by primary neurons cultured from the hippocampus and cortex of APP23 AD model mice (Li et al., 2011) . Hence, TTR is available to interact with A␤ either intracellularly or extracellularly. We believe that the results of the current experiments, coupled with those of others, describe the nature of the chemical interactions that may be involved. They are consistent with previously published data that neuronal TTR transcription is enhanced in human and mouse AD models in response to as yet undetermined signals (Stein et al., 2004) . It is unclear whether neuronal TTR production delays the onset of human AD or represents a failed natural defense against the toxic effects of A␤. In any case, the data we present here describe, to the greatest extent so far, the biophysical constraints governing what appears to be a biologically, and perhaps clinically, important protein-protein interaction that may be therapeutically exploitable.
